Debt

3 Months Ended

Mar. 31, 2020

DEBT

Senior Notes

The following describes all of our currently outstanding unsecured senior notes issued and sold in private placements (collectively, the "Senior Notes") as of March 31, 2020:



(Principal Amount in thousands)

Issue Date	Due Date	Series	Principal Amount		Coupon Rate		Senior Note Agreement⁽¹⁾

12/11/2013	12/11/2023	2023 Series A Notes	$	75,000	3.94	%	NY Life 2013 Note Agreement
12/11/2013	12/11/2025	2025 Series B Notes	$	75,000	4.04	%	NY Life 2013 Note Agreement
09/04/2014	09/04/2026	2026 Senior Notes	$	75,000	3.72	%	NY Life 2014 Note Agreement
07/21/2014	07/21/2021	2021 Series A Notes	$	50,000	3.32	%	Prudential 2015 Amended Agreement
07/21/2014	07/21/2024	2024 Series B Notes	$	75,000	3.76	%	Prudential 2015 Amended Agreement
06/18/2015	06/18/2025	2025 Series C Notes	€	88,857	1.785	%	Prudential 2015 Amended Agreement
02/12/2015	02/12/2022	2022 Series A Notes	$	75,000	3.25	%	MetLife 2014 Note Agreement
02/12/2015	02/12/2027	2027 Series B Notes	$	75,000	3.72	%	MetLife 2014 Note Agreement
03/14/2019	03/14/2029	2029 Series C Notes	$	100,000	4.19	%	MetLife 2014 Note Agreement

(1) In each case, as amended.

Senior Notes - Subsequent Event

The following describes unsecured senior notes issued and sold in private placements after March 31, 2020:

(Principal Amount in thousands)

Issue Date

Due Date

Series

Principal Amount

Coupon Rate

Senior Note Agreement ⁽¹⁾

04/02/2020

04/02/2030

MetLife 2030 Series D Notes

125,000

2.50

MetLife 2014 Note Agreement

04/14/2020

04/14/2030

Prudential 2030 Series D Notes

75,000

2.50

Prudential 2015 Amended Agreement

(1) In each case, as amended.

MetLife 2014 Note Agreement

On March 23, 2020, we entered into the Second Amendment to the MetLife 2014 Note Agreement (the “MetLife Second Amendment”), in order to (i) increase the facility size from $150 million to $300 million, (ii) extend the facility issuance period to December 20, 2022, (iii) make various implementing and administrative changes in order to facilitate a $125 million notes issuance on April 2, 2020 and (iv) allow the amount available to be issued under the facility to equal $300 million less the amount of notes outstanding from time to time during the issuance period.

On April 2, 2020, we issued and sold to MetLife and other purchasers $125 million of our unsecured senior notes (the “MetLife 2030 Series D Notes”) pursuant to the MetLife Second Amendment. The entire outstanding principal balance of the MetLife 2030 Series D Notes is due and payable on April 2, 2030, and the MetLife 2030 Series D Notes bear interest at the rate of 2.50% per annum. We anticipate using the proceeds received from the MetLife 2030 Series D Notes for general corporate purposes.

Prudential 2015 Amended Agreement

On April 10, 2020, we entered into the Second Amendment to the Prudential 2015 Amended Agreement (the “Prudential Second Amendment”), in order to (i) increase the facility size to $425 million, (ii) extend the facility issuance period to April 10, 2023, (iii) make various implementing and administrative changes in order to facilitate a $75 million notes issuance on April 14, 2020, (iv) allow the amount available to be issued under the facility to equal $425 million less the amount of notes outstanding from time to time during the issuance period and (v) modify several defined terms, schedules and covenant baskets in the Prudential 2015 Amended Agreement to create additional operating flexibility, and in particular to align such provisions with similar modifications we made substantially concurrently in our other debt facilities.

On April 14, 2020, we issued and sold to Prudential and other purchasers $75 million of our unsecured senior notes (the “Prudential 2030 Series D Notes”) pursuant to the Prudential Second Amendment. The entire outstanding balance of the Prudential 2030 Series D Notes is due and payable on April 14, 2030, and the Prudential 2030 Series D Notes bear interest at the rate of 2.50% per annum. We anticipate using the proceeds received from the Prudential 2030 Series D Notes for general corporate purposes.

NY Life 2013 and 2014 Note Agreements

On April 10, 2020, we amended the NY Life 2013 Note Agreement and the NY Life 2014 Note Agreement by entering into two Amendments to Note Purchase Agreement with New York Life Insurance Company and the other parties thereto, which modified several defined terms, schedules and covenant baskets in the NY Life 2013 Agreement and the NY Life 2014 Note Agreement to create additional operating flexibility, and in particular to align such provisions with similar modifications we made substantially concurrently in our other debt facilities.

Credit Facility - Subsequent Event

On April 14, 2020, we, along with IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX Europe B.V., and IDEXX Holding B.V., our wholly-owned subsidiaries (whether directly or indirectly held) (collectively, the “Borrowers”), entered into a third amended and restated credit agreement (the "Credit Agreement") relating to a three-year unsecured revolving credit facility in the principal amount of $1 billion, among the Borrowers, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto agent, and the other parties thereto.

The Credit Agreement amends and restates that certain second amended and restated credit agreement dated as of December 4, 2015, (which provided for a $850 million five-year unsecured revolving credit facility) to extend the maturity to April 14, 2023 and to increase the aggregate commitments available for borrowing by the Borrowers to $1 billion with the option to increase the aggregate commitments by $250 million, for an aggregate maximum of up to $1.25 billion, subject to the Borrowers obtaining commitments from existing or new lenders and satisfying other conditions specified in the Credit Agreement.